396 results on '"Yuan, Constance M."'
Search Results
2. COVID-19 vaccination in patients with classic and variant hairy cell leukemia
3. Rapid anti-myeloma activity by T cells expressing an anti-BCMA CAR with a human heavy-chain-only antigen-binding domain
4. COVID-19 in patients with classic and variant hairy cell leukemia
5. Preinfusion factors impacting relapse immunophenotype following CD19 CAR T cells
6. CD19/22 CAR T cells in children and young adults with B-ALL: phase 1 results and development of a novel bicistronic CAR
7. Characterization of extramedullary disease in B-ALL and response to CAR T-cell therapy
8. Clinical and biological implications of target occupancy in CLL treated with the BTK inhibitor acalabrutinib
9. Chimeric Antigen Receptor T Cells as Salvage Therapy for Post-Chimeric Antigen Receptor T Cell Failure
10. Chapter 4 - Flow Cytometry
11. Serial evaluation of CD19 surface expression in pediatric B-cell malignancies following CD19-targeted therapy
12. Preclinical Development of Bivalent Chimeric Antigen Receptors Targeting Both CD19 and CD22
13. Quantification of B-cell maturation antigen, a target for novel chimeric antigen receptor T-cell therapy in Myeloma
14. Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study
15. Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia
16. Non-V600E BRAF mutations and treatment for hairy cell leukemia
17. CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy
18. Supplementary Figures and Table from Modulation of Target Antigen Density Improves CAR T-cell Functionality and Persistence
19. Conflict of Interest Form from Disruption of in vivo Chronic Lymphocytic Leukemia Tumor–Microenvironment Interactions by Ibrutinib – Findings from an Investigator-Initiated Phase II Study
20. Supplementary tables and figure legends from Disruption of in vivo Chronic Lymphocytic Leukemia Tumor–Microenvironment Interactions by Ibrutinib – Findings from an Investigator-Initiated Phase II Study
21. Supplementary figures S1-S5 from Disruption of in vivo Chronic Lymphocytic Leukemia Tumor–Microenvironment Interactions by Ibrutinib – Findings from an Investigator-Initiated Phase II Study
22. Contributors
23. ‘A novel approach for characterisation of KSHV ‐associated multicentric Castleman disease from effusions’: R esponse
24. CD22low/Bcl-2high expression identifies poor response to inotuzumab ozogamicin in relapsed/refractory acute lymphoblastic leukemia
25. Daratumumab induces cell-mediated cytotoxicity of primary effusion lymphoma and is active against refractory disease
26. Flow cytometric differentiation of abnormal and normal plasma cells in the bone marrow in patients with multiple myeloma and its precursor diseases
27. Circulating CD22 +/ CD19 −/ CD24 − progenitors and CD22 +/ CD19 +/ CD24 − mature B cells: Diagnostic pitfalls for minimal residual disease detection in B‐lymphoblastic leukemia
28. T Cells Expressing a Fully-Human Anti-BCMA Chimeric Antigen Receptor with a Heavy-Chain-Only Antigen-Recognition Domain Exhibit Rapid and Durable Activity Against Multiple Myeloma
29. A novel approach for characterization of KSHV ‐associated multicentric Castleman disease from effusions
30. Distinguishing hairy cell leukemia variant from hairy cell leukemia: Development and validation of diagnostic criteria
31. Anti-CD22–chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia
32. Circulating CD22+/CD19−/CD24− progenitors and CD22+/CD19+/CD24− mature B cells: Diagnostic pitfalls for minimal residual disease detection in B‐lymphoblastic leukemia.
33. Role of Flow Cytometry of Peripheral Blood and Bone Marrow Aspirates in Early Myeloma
34. Efficacy of second CAR-T (CART2) infusion limited by poor CART expansion and antigen modulation
35. Acute and delayed cytopenias following CAR T-cell therapy: an investigation of risk factors and mechanisms
36. Phase II Trial of Inotuzumab Ozogamicin in Children and Adolescents With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia: Children's Oncology Group Protocol AALL1621
37. Blinatumomab Nonresponse and High-Disease Burden Are Associated With Inferior Outcomes After CD19-CAR for B-ALL
38. Chronic Lymphocytic Leukemia, the Prototypic Chronic Leukemia for Flow Cytometric Analysis
39. Characterization of CD22 Expression in Acute Lymphoblastic Leukemia
40. Treatment of Patients with T Cells Expressing a Fully-Human Anti-BCMA CAR with a Heavy-Chain Antigen-Recognition Domain Caused High Rates of Sustained Complete Responses and Relatively Mild Toxicity
41. CD22 low/Bcl-2 high Expression Identifies Poor Response to Inotuzumab in Relapsed/ Refractory Acute Lymphoblastic Leukemia
42. KMT2A Rearrangements Are Associated with Lineage Switch Following CD19 Targeting CAR T-Cell Therapy
43. Treatment of HIV-associated primary CNS lymphoma with antiretroviral therapy, rituximab, and high-dose methotrexate
44. Treatment of High Risk (HR) Smoldering Multiple Myeloma (SMM) with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Followed By Lenalidomide Maintenance (-R): A Phase 2 Clinical and Correlative Study
45. Non-V600E BRAFmutations and treatment for hairy cell leukemia
46. Fixed Duration Combination Therapy with Carfilzomib, Lenalidomide, and Dexamethasone Followed By Lenalidomide Maintenance Leads to High Rates of Sustained MRD Negativity in Patients with High-Risk Smoldering Multiple Myeloma: Long Term Follow up of an Investigator Initiated Phase 2 Trial
47. Long-Term Outcomes in Chronic Lymphocytic Leukemia Treated with Ibrutinib: 10-Year Follow-up of a Phase 2 Study
48. CD33 CAR T-Cells (CD33CART) for Children and Young Adults with Relapsed/Refractory AML: Dose-Escalation Results from a Phase I/II Multicenter Trial
49. Long-Term Follow-Up of CD19-CAR T-Cell Therapy in Children and Young Adults With B-ALL
50. Intensity of antigen expression reflects IGHV mutational status and Dohner-defined prognostic categories in chronic lymphocytic leukemia, monoclonal B-cell lymphocytosis, and small lymphocytic lymphoma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.